Selecxine is a biopharmaceutical development company specialized in the field of immunotherapeutics.
Selecxine strives to develop immunotherapeutics – a new paradigm of pharmaceuticals– through a specialized antibody development process, using an innovative platform technology of functional antibody screening and development.
We endeavor to improve the survival rate and quality of life of cancer patients by developing anti-cancer immunotherapeutics that selectively stimulate the immune cells. These agents act against tumor cells through the regulation of cytokine function, which plays a key role in the enter cell activities.
Based on our technology and expertise in the pharmacology and development field,
we aim to provide safe and efficient therapeutics and innovative solutions for
next-generation pharmaceuticals.
CEO, Selecxine Inc. Jun-Young Lee
Company Details
- Employees
- 8
- Founded
- -
- Address
- 서울특별시 송파구 송파대로 167번지 05855, 테라타워 B-1101,korea, Republic Of
- Industry
- Biotechnology
- Website
- http://www.selecxine.com/
- HQ
- B-1101, 167, Songpa-daero, Songpa-gu, Seoul, 05855, Republic of Korea
Selecxine Questions
Selecxine's website is http://www.selecxine.com/
Selecxine's LinkedIn profile is https://kr.linkedin.com/company/selecxine
Selecxine has
8 employees.
View email and phone details for 8
employees at Selecxine.
Selecxine's industry is
Biotechnology
Selecxine's top competitors are
Idience,
Intocell Inc,
Novotech,
Ilias Biologics Inc.,
Amicogen, Inc.,
C&r Research, Inc,
Qurient, Inc.,
Astrazeneca,
Fortrea,
Gradiant Bioconvergence.
Selecxine's categories are Biotechnology
Selecxine's founding year is 2018
